Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.

NCT Number	NCT07252050
Lead Sponsor	Arkansas Children's Hospital Research Institute Collaborators: Children's Healthcare of Atlanta, Emory University, Incyte Corporation
Conditions	Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure
Enrollment	24 participants
Start Date	2026-06-08
Primary Completion	2028-11-19 (estimated)
Study Completion	2029-11-19 (estimated)
Updated on ClinicalTrials.gov	2026-06-04